항균제 시장 : 약물 종류별, 투여 경로별, 활성 스펙트럼별, 작용기전별, 적응증별, 판매 거점별, 유통 채널별 - 세계 예측(2025-2030년)

The Antibacterial Drugs Market was valued at USD 51.77 billion in 2024 and is projected to grow to USD 54.05 billion in 2025, with a CAGR of 4.54%, reaching USD 67.59 billion by 2030.

Introduction

Antibacterial drugs have long been a cornerstone of modern medicine, offering critical defense against microbial infections. In an era marked by rapid scientific advances and an evolving disease profile, the development and utilization of antibacterial agents remain as crucial as ever. The ongoing challenge of antimicrobial resistance, coupled with breakthroughs in pharmaceutical research and development, has catalyzed a renewed global focus on expanding the antibacterial drugs market. This report provides a comprehensive overview of the current state of antibacterial drugs, detailing technological innovations, regulatory updates, and emerging market opportunities. Readers will gain insight into the complexity of antibacterial therapies and the interplay between drug development, market segmentation, and regional industry dynamics.

Transformative Shifts in the Landscape

The antibacterial drugs market has witnessed transformative changes that are reshaping its dynamics. Key shifts include an acceleration in research and development activities that are driving innovations across the production of both novel compounds and restructured formulations of existing molecules. Advanced technologies such as high-throughput screening, computational modeling, and genomic approaches have paved the way for the discovery of new targets and mechanisms to combat resistant strains. Regulatory agencies across different regions are adapting faster to the evolving scenario by offering expedited review processes and streamlined pathways to approval, further spurring innovation.

In parallel, the healthcare ecosystem is increasingly prioritizing precision medicine and individualized therapeutic regimens. The need for targeted antibacterial agents that minimize collateral damage to the host microbiome is at the forefront. This trend is supported by robust investments in mechanistic studies that provide greater insight into the modes of action of antibacterial drugs. In addition, the emergence of combination therapies and adjuvant treatments has added a layer of sophistication to traditional treatment paradigms, ensuring that therapies remain viable even in the face of emerging resistance mechanisms. Collectively, these transformative shifts have redefined market entry strategies and built new layers of competition among global players, while simultaneously opening the door for niche interventions that cater to specific patient demographics and infection profiles.

Key Segmentation Insights

An in-depth analysis of market segmentation provides critical insight into the multifaceted antibacterial drugs landscape. The drug class segmentation categorizes treatments by the biochemical properties and mechanisms of action. This segmentation is broken down into major classes such as Aminoglycosides, Beta-Lactams, Glycopeptides, Lincosamides, Macrolides, Quinolones, Sulfonamides, and Tetracyclines; each of which is further studied by its unique compounds. Within the Aminoglycosides category, compounds including Amikacin, Gentamicin, Neomycin, Plazomicin, Streptomycin, and Tobramycin are examined, while the Beta-Lactams category delves into Compound-specific data for Carbapenems, Cephalosporins, Monobactams, and Penicillins. Glycopeptides are scrutinized based on therapies such as Dalbavancin, Oritavancin, Teicoplanin, and Vancomycin, and similar detailed analytical approaches are applied to Lincosamides with agents like Clindamycin and Lincomycin, Macrolides with products including Azithromycin, Clarithromycin, Erythromycin, and Fidaxomicin, followed by Quinolones examining Ciprofloxacin, Delafloxacin, and Gemifloxacin. Additional layers are provided by examining Sulfonamides, which cover compounds such as Sulfadiazine, Sulfadoxine, and Sulfamethoxazole-Trimethoprim, together with Tetracyclines that focus on Doxycycline, Minocycline, Tetracycline, and Tigecycline.

Another important segmentation considers routes of administration. Market insights are deduced from examining how drugs are delivered into the system via Inhalation, Intramuscular, Intravenous, Oral, Subcutaneous, and Topical means. Each route presents unique challenges and opportunities, particularly when aligning dosage forms with patient compliance and pharmacokinetic profiles. Similarly, segmentation based on the spectrum of activity categorizes products as Broad-Spectrum versus Narrow-Spectrum agents, an analytical distinction that supports both clinical decision-making and regulatory approvals. Further refinement is seen in segmentation according to mechanism of action, where drugs are grouped based on their ability to inhibit cell wall synthesis, nucleic acid synthesis, protein synthesis, ATP synthase activity, or affect membrane functions and metabolic pathways. The wide-ranging indications for antibacterial drugs are also central to segmentation, with clinical applications spanning Respiratory Infections, Sexually Transmitted Infections, Skin Infections, and Urinary Tract Infections. Equally influential is the segmentation based on the point of sale, delineating products as Over-The-Counter or Prescription Drugs, which affects distribution and market penetration. Finally, a segmentation based on the distribution channel distinguishes between Offline and Online sales, with Offline channels being further evaluated by their performance in Hospital Pharmacy and Retail Pharmacy environments. These segmentation dimensions collectively provide robust insights that enable stakeholders to tailor their strategies and respond effectively to the evolving market demands.

Based on Drug Class, market is studied across Aminoglycosides, Beta-Lactams, Glycopeptide, Lincosamides, Macrolides, Quinolones, Sulfonamides, and Tetracyclines. The Aminoglycosides is further studied across Amikacin, Gentamicin, Neomycin, Plazomicin, Streptomycin, and Tobramycin. The Beta-Lactams is further studied across Carbapenems, Cephalosporins, Monobactams, and Penicillins. The Glycopeptide is further studied across Dalbavancin, Oritavancin, Teicoplanin, and Vancomycin. The Lincosamides is further studied across Clindamycin and Lincomycin. The Macrolides is further studied across Azithromycin, Clarithromycin, Erythromycin, and Fidaxomicin. The Quinolones is further studied across Ciprofloxacin, Delafloxacin, and Gemifloxacin. The Sulfonamides is further studied across Sulfadiazine, Sulfadoxine, and Sulfamethoxazole-Trimethoprim. The Tetracyclines is further studied across Doxycycline, Minocycline, Tetracycline, and Tigecycline.

Based on Route of Administration, market is studied across Inhalation, Intramuscular, Intravenous, Oral, Subcutaneous, and Topical.

Based on Spectrum of Activity, market is studied across Broad-Spectrum and Narrow-Spectrum.

Based on Mechanism of Action, market is studied across Inhibit Cell Wall Synthesis, Inhibit Nucleic Acid Synthesis, Inhibit Protein Synthesis, Inhibitor of ATP Synthase, Inhibitors of Membrane Function, and Inhibitors of Metabolic Pathways.

Based on Indication, market is studied across Respiratory Infections, Sexually Transmitted Infections, Skin Infections, and Urinary Tract Infections.

Based on Point of Sale, market is studied across Over-The-Counter Drugs and Prescription Drugs.

Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Retail Pharmacy.

Key Regional Insights

The antibacterial drugs market exhibits significant heterogeneity across different global regions, reinforcing the need for tailored strategies that accommodate local dynamics. In the Americas, advanced healthcare infrastructure and heightened public awareness about antimicrobial resistance have driven significant investment in research, fostering a dynamic market characterized by rapid adoption of innovative therapies. Meanwhile, Europe, Middle East & Africa has witnessed a consolidation of regulatory policies and a strategic focus on combating resistance through coordinated public health initiatives and cross-border collaborations. Regulatory frameworks in these regions promote accelerated approvals for breakthrough technologies while ensuring that safety and efficacy remain paramount. Across Asia-Pacific, rapid economic growth, coupled with increasing healthcare expenditures and expanding access to advanced medical practices, has intensified the demand for both new and improved antibacterial agents. In these regions, the burgeoning middle class and improved health literacy have collectively encouraged wider use of both prescription and over-the-counter treatments. These regional insights underscore the importance of considering cultural, economic, and regulatory differences when devising market entry and expansion strategies in the antibacterial drugs domain.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

The antibacterial drugs market is marked by the active involvement of several key companies, each contributing to the industry's forward momentum through a blend of innovation, strategic mergers, and robust product portfolios. Major players such as Abbott Laboratories, AbbVie Inc., and Allecra Therapeutics GmbH continue to invest heavily in cutting-edge research while expanding their product offerings. Astellas Pharma Inc. and AstraZeneca PLC, with their rich histories and extensive networks, consistently drive market penetration through innovative therapeutic strategies. Bausch Health Companies Inc. and Bayer AG have strengthened their positions by harnessing diagnostic advancements that enhance treatment specificity, while Bristol-Myers Squibb Company and Century Pharmaceuticals Ltd. maintain their commitment to broadening therapeutic horizons. Companies like Cipla Limited and Debiopharm Group couple extensive market reach with robust research endeavors. Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, and Entasis Therapeutics by Innoviva, Inc. have also cut a niche for themselves by concentrating on targeted antibacterial solutions, ensuring that diverse patient needs are met. F. Hoffmann-La Roche AG and GlaxoSmithKline PLC continue to be stalwarts of the industry, offering a wide range of products supported by significant research investments. Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, and Iterum Therapeutics PLC have further diversified the competitive landscape by merging traditional practices with modern science. Johnson & Johnson Services, Inc. along with Kyorin Pharmaceutical Co., Ltd., Lupin Limited, and Melinta Therapeutics LLC also play pivotal roles, influencing global trends and ensuring product accessibility. The contributions of Merck & Co., Inc., Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd., Novartis AG, and Pfizer Inc. are pivotal in setting benchmarks for excellence, with Sanofi S.A. and Saphnix Life Sciences strengthening the research interface between academia and the pharmaceutical industry. Shionogi & Co., Ltd., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd. round off the cohort of influential companies that continuously shape market trends and propel innovative antibacterial therapeutics.

The report delves into recent significant developments in the Antibacterial Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Allecra Therapeutics GmbH, Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Century Pharmaceuticals Ltd., Cipla Limited, Debiopharm Group, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Entasis Therapeutics by Innoviva, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Iterum Therapeutics PLC, Johnson & Johnson Services, Inc., Kyorin Pharmaceutical Co., Ltd., Lupin Limited, Melinta Therapeutics LLC, Merck & Co., Inc., Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., Saphnix Life Sciences, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders in the antibacterial drugs market are encouraged to adopt a multi-pronged strategic approach in response to the continuously evolving landscape. First, stakeholders must significantly increase investments in basic and translational research targeting emerging resistance patterns, harnessing modern technologies that accelerate compound discovery and the development of efficacy-enhancing formulations. A close alliance with academic institutions and biotechnology innovators will be crucial to translating research insights into viable products. Second, companies should streamline their regulatory interphase processes and foster advocacy channels with government bodies to secure accelerated approvals without compromising on safety or efficacy benchmarks. This collaborative approach will be particularly vital in regions where regulatory frameworks are undergoing rapid transitions.

In addition, an optimized segmentation strategy can serve as a competitive differentiator. Organizations should invest in sophisticated market analytics to track evolving patient and prescriber needs, thereby allowing them to refine product portfolios based on drug class, route of administration, and spectrum of activity. Tailoring therapeutic solutions across diverse indications such as respiratory, urinary, skin, and sexually transmitted infections will enhance market relevance. Moreover, one should also focus on mechanisms of action as an integral segmentation tool, categorizing treatments according to their precision in inhibiting pathogen structures, metabolic pathways, or other critical processes. This granularity not only informs targeted marketing campaigns but also assists in achieving regulatory endorsements.

A forward-thinking distribution strategy is equally critical. Industry leaders should leverage both offline and online channels to broaden market reach while ensuring that product quality and patient safety remain uncompromised. Strategic alliances with hospital pharmacies and retail networks can drive penetration in traditionally robust offline sectors, while collaborative digital initiatives can capture the growing segment of online buyers. Finally, a clear focus on sustainability, patient-centric outcomes, and ethical drug promotion practices will build trust with healthcare professionals and end-consumers alike. Embracing these recommendations will empower industry leaders to not only navigate the complex antibacterial landscape but also to seize opportunities for sustainable growth and competitive advantage.

Conclusion

In conclusion, the antibacterial drugs market is at a pivotal juncture, driven by a synthesis of scientific innovation, regulatory reform, and robust market segmentation. The evolving landscape has redefined research paradigms and spurred the growth of innovative therapies that effectively challenge drug-resistant pathogens. A comprehensive understanding of segmentation-across drug classes, administration routes, spectrum of activity, mechanisms of action, clinical indications, points of sale, and distribution channels-proves vital to navigating this multifaceted market. The regional disparities and specific market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific further underscore the importance of localized and adaptive strategies.

The collective efforts of leading companies have paved the way for advancements that not only fulfill current market needs but also anticipate future trends. With a focus on strategic investments, partnerships, and technological integration, the antibacterial drugs landscape is poised for robust growth, enabling providers to deliver more precise and effective treatments. Ultimately, the synthesis of detailed market insights and actionable recommendations equips stakeholders with the necessary framework to navigate the ongoing challenges and tap into emerging growth opportunities in a competitive environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence and spread of infectious diseases enhancing the need for antibacterial solutions
    • 5.1.1.2. Increasing incidence of hospital-acquired infections need for advanced antibacterial drugs
    • 5.1.1.3. Rising government initiatives for antibacterial drug research and development
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall issue associated with antibacterial drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in drug formulation and delivery technology opening new avenues for antibacterial drugs
    • 5.1.3.2. Ongoing public-private collaboration for advancement of antibacterial drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Limited efficacy against multi-drug resistant pathogens and risk of adverse side effects
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Increasing need of Beta-Lactams due to their broad-spectrum efficacy, and proven safety profile
  • 5.2.2. Route of Administration: Rising adoption of oral antibacterial drugs due to their ease of administration
  • 5.2.3. Spectrum of Activity: Prefernce for narrow-spectrum antibacterial drugs for more precise treatment
  • 5.2.4. Mechanism of Action: Need for an antibacterial drug that inhibits nucleic acid synthesis to prevent bacteria from proliferating
  • 5.2.5. Indication: Advancing precision in urinary tract infection management through innovative antibacterial therapies
  • 5.2.6. Point of Sale: Growing demand for over-the-counter antibacterial drug to enhancing accessibility
  • 5.2.7. Distribution Channel: Rising preference for online to secure home delivery services
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibacterial Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Aminoglycosides
  • 6.2.1. Amikacin
  • 6.2.2. Gentamicin
  • 6.2.3. Neomycin
  • 6.2.4. Plazomicin
  • 6.2.5. Streptomycin
  • 6.2.6. Tobramycin
• 6.3. Beta-Lactams
  • 6.3.1. Carbapenems
  • 6.3.2. Cephalosporins
  • 6.3.3. Monobactams
  • 6.3.4. Penicillins
• 6.4. Glycopeptide
  • 6.4.1. Dalbavancin
  • 6.4.2. Oritavancin
  • 6.4.3. Teicoplanin
  • 6.4.4. Vancomycin
• 6.5. Lincosamides
  • 6.5.1. Clindamycin
  • 6.5.2. Lincomycin
• 6.6. Macrolides
  • 6.6.1. Azithromycin
  • 6.6.2. Clarithromycin
  • 6.6.3. Erythromycin
  • 6.6.4. Fidaxomicin
• 6.7. Quinolones
  • 6.7.1. Ciprofloxacin
  • 6.7.2. Delafloxacin
  • 6.7.3. Gemifloxacin
• 6.8. Sulfonamides
  • 6.8.1. Sulfadiazine
  • 6.8.2. Sulfadoxine
  • 6.8.3. Sulfamethoxazole-Trimethoprim
• 6.9. Tetracyclines
  • 6.9.1. Doxycycline
  • 6.9.2. Minocycline
  • 6.9.3. Tetracycline
  • 6.9.4. Tigecycline

7. Antibacterial Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhalation
• 7.3. Intramuscular
• 7.4. Intravenous
• 7.5. Oral
• 7.6. Subcutaneous
• 7.7. Topical

8. Antibacterial Drugs Market, by Spectrum of Activity

• 8.1. Introduction
• 8.2. Broad-Spectrum
• 8.3. Narrow-Spectrum

9. Antibacterial Drugs Market, by Mechanism of Action

• 9.1. Introduction
• 9.2. Inhibit Cell Wall Synthesis
• 9.3. Inhibit Nucleic Acid Synthesis
• 9.4. Inhibit Protein Synthesis
• 9.5. Inhibitor of ATP Synthase
• 9.6. Inhibitors of Membrane Function
• 9.7. Inhibitors of Metabolic Pathways

10. Antibacterial Drugs Market, by Indication

• 10.1. Introduction
• 10.2. Respiratory Infections
• 10.3. Sexually Transmitted Infections
• 10.4. Skin Infections
• 10.5. Urinary Tract Infections

11. Antibacterial Drugs Market, by Point of Sale

• 11.1. Introduction
• 11.2. Over-The-Counter Drugs
• 11.3. Prescription Drugs

12. Antibacterial Drugs Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
  • 12.2.1. Hospital Pharmacy
  • 12.2.2. Retail Pharmacy
• 12.3. Online

13. Americas Antibacterial Drugs Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Antibacterial Drugs Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Antibacterial Drugs Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Oxford Drug Design secures GBP 1M funding to advance uUTI therapeutics
  • 16.3.2. FDA approval of Emblaveo for resistant gram-negative infections
  • 16.3.3. CARB-X invests in innovative peptide antibiotic targeting gram-negative bacteria
  • 16.3.4. Wockhardt secures CDSCO approval for Miqnaf for innovative CABP treatment
  • 16.3.5. Zai Lab and Pfizer forge strategic collaboration on novel antibacterial drug XACDURO
  • 16.3.6. FDA approves ORLYNVAH for uncomplicated urinary tract infections
  • 16.3.7. Orchid Pharma partner with Cipla Unite to launch new antibiotic in India
  • 16.3.8. Allecra Therapeutics and Acino secure exclusive licensing deal to commercialize EXBLIFEP antibiotic
  • 16.3.9. Lupin Launches generic Doxycycline injection in US
  • 16.3.10. FDA approves Zevtera for multiple bacterial infections
  • 16.3.11. Lupin secures FDA approval for generic doxycycline injection
  • 16.3.12. Basilea acquires novel preclinical antibiotics program from Spexis
• 16.4. Strategy Analysis & Recommendation
  • 16.4.1. Pfizer Inc.
  • 16.4.2. Lupin Limited
  • 16.4.3. Cipla Limited
  • 16.4.4. Glenmark Pharmaceuticals Limited

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Allecra Therapeutics GmbH
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bausch Health Companies Inc.
• 7. Bayer AG
• 8. Bristol-Myers Squibb Company
• 9. Century Pharmaceuticals Ltd.
• 10. Cipla Limited
• 11. Debiopharm Group
• 12. Dr. Reddy's Laboratories Ltd.
• 13. Eli Lilly and Company
• 14. Entasis Therapeutics by Innoviva, Inc.
• 15. F. Hoffmann-La Roche AG
• 16. GlaxoSmithKline PLC
• 17. Glenmark Pharmaceuticals Limited
• 18. Hikma Pharmaceuticals PLC
• 19. Iterum Therapeutics PLC
• 20. Johnson & Johnson Services, Inc.
• 21. Kyorin Pharmaceutical Co., Ltd.
• 22. Lupin Limited
• 23. Melinta Therapeutics LLC
• 24. Merck & Co., Inc.
• 25. Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
• 26. Novartis AG
• 27. Pfizer Inc.
• 28. Sanofi S.A.
• 29. Saphnix Life Sciences
• 30. Shionogi & Co., Ltd.
• 31. Sun Pharmaceutical Industries Limited
• 32. Taj Pharmaceuticals Limited
• 33. Teva Pharmaceutical Industries Ltd.